ATE504309T1 - Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis - Google Patents

Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis

Info

Publication number
ATE504309T1
ATE504309T1 AT02701842T AT02701842T ATE504309T1 AT E504309 T1 ATE504309 T1 AT E504309T1 AT 02701842 T AT02701842 T AT 02701842T AT 02701842 T AT02701842 T AT 02701842T AT E504309 T1 ATE504309 T1 AT E504309T1
Authority
AT
Austria
Prior art keywords
cervicitis
situ
pharmaceutical composition
oxytocin
preparing
Prior art date
Application number
AT02701842T
Other languages
English (en)
Inventor
Kerstin Uvnaes-Moberg
Thomas Lundeberg
Original Assignee
Kerstin Uvnaes-Moberg
Thomas Lundeberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kerstin Uvnaes-Moberg, Thomas Lundeberg filed Critical Kerstin Uvnaes-Moberg
Application granted granted Critical
Publication of ATE504309T1 publication Critical patent/ATE504309T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02701842T 2001-02-28 2002-02-28 Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis ATE504309T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0100684A SE0100684D0 (sv) 2001-02-28 2001-02-28 New subject-matter
PCT/SE2002/000362 WO2002067974A1 (en) 2001-02-28 2002-02-28 Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis

Publications (1)

Publication Number Publication Date
ATE504309T1 true ATE504309T1 (de) 2011-04-15

Family

ID=20283165

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02701842T ATE504309T1 (de) 2001-02-28 2002-02-28 Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis

Country Status (7)

Country Link
US (1) US7405200B2 (de)
EP (1) EP1370277B1 (de)
JP (1) JP2004527496A (de)
AT (1) ATE504309T1 (de)
DE (1) DE60239670D1 (de)
SE (1) SE0100684D0 (de)
WO (1) WO2002067974A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0001440D0 (sv) * 2000-04-18 2000-04-18 Entretech Medical Ab A drug against climacteric disorders
AR038085A1 (es) * 2002-12-27 2004-12-29 Univ Nac Quilmes Analogos de 1-desamino-8-d-arginina vasopresina
WO2009033665A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a rgd-peptide and/or parathyroid hormone (1-34 ) as anti-hiv agent
JP2010538979A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Ｓ．Ｐｎｅｕｍｏｎｉａｅの感染等を処置するための治療剤としての、ＲＧＤＳＰＡＳＳＫＰ、および随意的なアンギオテンシンＩＩの使用
JP2010539002A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト ウロジラチンの治療剤としての使用
WO2009033820A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
KR20100056508A (ko) * 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 폐렴 연쇄상 구균 감염의 치료를 위한 ｂｆｇｆ １－２４ 및 임의의 （ａｒｇ ８）바소프레신의 용도
SE536091C2 (sv) * 2011-04-14 2013-04-30 Pep Tonic Medical Ab Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter
US11414459B2 (en) 2017-09-28 2022-08-16 Kinoxis Therapeutics Pty Ltd Metabolite inspired selective oxytocin receptor agonists
WO2020137880A1 (ja) * 2018-12-27 2020-07-02 国立大学法人北海道大学 オキシトシン誘導体及びその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE430885B (sv) * 1980-03-24 1983-12-19 Ferring Ab Oxytocin-derivat
CS255616B1 (cs) * 1986-07-18 1988-03-15 Petr Simek Způsob výroby (2-0-metyltyrosin)deamino-1-karbaoxytocinu
DE4229878A1 (de) * 1992-09-04 1994-03-10 Knauf Siegfried Neues Medikament "Oxytocin" zur Bekämpfung der Zuckerkrankheit Typ 1
DE4236293A1 (en) 1992-10-23 1993-03-04 Siegfried Knauf Use of oxytocin, vasopressin and endorphins - for treatment and prevention of e.g. immunological, neurological and organ diseases and conditions caused by pituitary disorder
DE4244639A1 (de) * 1992-10-23 1994-07-07 Knauf Siegfried Medikament bzw. Medikamentenzusammensetzung
GB9326354D0 (en) 1993-12-23 1994-02-23 British Aerospace Methods and apparatus for the testing,monitoring and improvement of manufacturing process effectiveness
SE9701161D0 (sv) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use I
SE9701162D0 (sv) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use II
SE9803272D0 (sv) 1998-09-25 1998-09-25 Kerstin Uvnaes Moberg A drug for cell regeneration
SE0001440D0 (sv) 2000-04-18 2000-04-18 Entretech Medical Ab A drug against climacteric disorders
SE0102910D0 (sv) * 2001-08-31 2001-08-31 Moberg Kerstin Uvnaes New use

Also Published As

Publication number Publication date
EP1370277A1 (de) 2003-12-17
US20040176284A1 (en) 2004-09-09
US7405200B2 (en) 2008-07-29
DE60239670D1 (de) 2011-05-19
JP2004527496A (ja) 2004-09-09
SE0100684D0 (sv) 2001-02-28
WO2002067974A1 (en) 2002-09-06
EP1370277B1 (de) 2011-04-06

Similar Documents

Publication Publication Date Title
ATE204754T1 (de) Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
DE69840909D1 (de) Analoge von kokain
ATE248599T1 (de) Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen
DE69736183D1 (de) Verwendung von topiramat oder derivate davon zur herstellung eines arzneimittels zur behandlung von manisch-depressiven bipolaren störungen
IL197686A0 (en) Pharmaceutical compositions containing alpha-4 integrin antagonists and uses thereof in the treatment of multiple myeloma and diseases associated therewith
ATE242238T1 (de) Chinolin- und chinazolin-verbindungen von therapeutischem nutzen, insbesondere zur behandlung von gutartiger prostatahyperplasie
EP0948327A4 (de) Antidiabetische mittel
ATE495187T1 (de) Dalda-analoge und ihre verwendung
ATE504309T1 (de) Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
ATE218860T1 (de) Verwendung von 3,4-diphenylchromanen zur herstellung eines arzneimittels zur behandlung bzw. vorbeugung des prostatakarzinoms
DE60129829D1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE231131T1 (de) Verbindungen mit wachtumshormon freisetzenden eigenschaften
EP1401467A4 (de) Alpha-fetoprotein-peptide und ihre verwendung
ATE246518T1 (de) Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
DE69233725D1 (de) Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
DE60015791D1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE60224884D1 (de) Verfahren zur herstellung von 3, 3', 6, 6'-tetraalkylen-2, 2'-biphenolen und 3, 3', 6, 6'-tetraalkylen-5, 5'-dihalo-2, 2' biphenolen
FI951759A0 (fi) Menetelmä 2,2-difluoriketeenisilyyli-O,S-asetaalien ja alfa, alfa-difluori-beta-silyylioksi-1,3-dioksolaani-4-propaanihapon O,S-estereiden valmistamiseksi
DE69812438T2 (de) Zusammensetzung zur herstellung von brennstoff-briketts
DE60114597D1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
DE60022070D1 (de) Verwendung von stickstoffoxid zur behandlung von atemwegs-verengungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties